Revvity Inc RVTY

Morningstar Rating
$151.53 +2.47 (1.66%)
View Full Chart

Company Report

No-Moat Revvity Sees Solid First-Half Performance With Momentum Likely to Continue

Revvity, formerly PerkinElmer, has undergone a major transformation over the past decade. Following the 2023 divestiture of its applied, food, and enterprise services business, the firm rebranded as Revvity and now operates through two core segments, diagnostics and life sciences, with a strategic focus on enabling scientific breakthroughs and improving health outcomes.

Price vs Fair Value

RVTY is trading at a LOCK|^#>Rvm premium.
Price
$149.06
Fair Value
LOCK|@V
Uncertainty
LOCK|r$Q
1-Star Price
LOCK|>.>
5-Star Price
LOCK|.#
Economic Moat
LOCK|xJ
Capital Allocation
LOCK|^&&

Bulls Say, Bears Say

Bulls

Revvity possesses a well-entrenched niche in newborn screening and stands to benefit from growing menu expansion globally and expanding to emerging markets, particularly China and India.

Bears

Declining birthrates and overpopulation in China and India could slow Revvity's growth in diagnostics, particularly in newborn screening.

News

Trading Information

Previous Close Price
$149.06
Day Range
$148.55–153.38
52-Week Range
$81.22–158.28
Bid/Ask
$149.21 / $154.05
Shares Outstanding
111.59M
Market Cap
$16.91B
Volume/Avg
1M / 2M

Key Statistics

Price/Earnings (Normalized)
27.86
Price/Sales
5.79
Dividend Yield (Trailing)
0.19%
Dividend Yield (Forward)
0.19%
Dividend Payment Schedule
Feb, May, Aug, Nov
Total Yield
3.05%

Company Profile

Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity’s products and services are sold worldwide, with major markets in the US, Europe, and China.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Core
Total Number of Employees
11,000

Competitors

Valuation

Metric
RVTY
A
WAT
Price/Earnings (Normalized)
27.8627.5031.11
Price/Book Value
2.306.382.75
Price/Sales
5.796.416.86
Price/Cash Flow
23.0524.9126.54
Price/Earnings
RVTY
A
WAT

Financial Strength

Metric
RVTY
A
WAT
Quick Ratio
1.361.411.05
Current Ratio
1.802.051.86
Interest Coverage
9.5216.082.23
Quick Ratio
RVTY
A
WAT

Profitability

Metric
RVTY
A
WAT
Return on Assets (Normalized)
2.31%13.27%7.79%
Return on Equity (Normalized)
3.83%24.92%13.28%
Return on Invested Capital (Normalized)
3.21%16.95%10.35%
Return on Assets
RVTY
A
WAT

Diagnostics & Research Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
LOCK|CWg$KjzJLOCK|v#L$241B
Danaher Corp
DHR
LOCK|kk&#VB@$LOCK|!!$149B
Agilent Technologies Inc
A
LOCK|Rqmr!&ZLOCK|?^b$47B
IQVIA Holdings Inc
IQV
LOCK|?XHQ$hLLOCK|M>^<$43B
Waters Corp
WAT
LOCK|fX###mzLOCK|!y%$42B
IDEXX Laboratories Inc
IDXX
LOCK|%<@$yy#RLOCK|X<$41B
Illumina Inc
ILMN
LOCK|$&zRskLOCK|LqKJf$40B
Mettler-Toledo International Inc
MTD
LOCK|nL%Y^h#PLOCK|d^Zn$30B
Quest Diagnostics Inc
DGX
LOCK|&gy<$>LOCK|s^Hy$26B
Labcorp Holdings Inc
LH
LOCK|^KGS^@@LOCK|H&d<y$25B

Sponsor Center